Results 51 to 60 of about 98,704 (296)
American Journal of Medical Genetics Part A, EarlyView.ABSTRACT Griscelli Syndrome Type 2 (GS2) is a rare autosomal recessive disorder caused by pathogenic mutations in the RAB27A gene. Typically, it is characterized by cutaneous hypopigmentation, immunodeficiency, with or without neurological abnormalities secondary to hemophagocytic lymphohistiocytosis (HLH). Without treatment, GS2 often results in fatal
Dzhoy Papingi +6 more
wiley +1 more source
International Forum of Allergy &Rhinology, EarlyView.ABSTRACT Background Identifying predictive and monitoring biomarkers for allergen immunotherapy response is crucial for enhancing clinical efficacy. This study aims to investigate the systemic and local levels of immunoglobulins and identify potential biomarkers in house dust mite (HDM) allergic rhinitis (AR) patients who are undergoing subcutaneous ...
Xu Xu +6 more
wiley +1 more source
Medical Journal of BabylonBackground: Herpes viruses like cytomegalovirus (CMV) and Epstein–Barr virus (EBV) can cause serious illness in those who already have impaired immune systems. Objectives: The purpose of this research was to examine the impact of CMV and EBV infection on
Eman Ammar Ihsan +2 more
doaj +1 more source
Epstein Barr Virus Associated B-Cell Lymphomas and Iatrogenic Lymphoproliferative Disorders
Frontiers in Oncology, 2019 Epstein-Barr virus (EBV) is a ubiquitous herpesvirus, affecting up to 90% of the population. EBV was first identified as an oncogenic virus in a Burkitt lymphoma cell line, though subsequently has been found to drive a variety of malignancies, including ...
Jennifer L. Crombie, Ann S. LaCasce
doaj +1 more source
International Forum of Allergy &Rhinology, EarlyView.ABSTRACT Background Although shifts in nasal microbiota have been well‐documented in inflammatory upper airway conditions, microbiota tumor‐associated alterations remain uncharacterized. This study is the first to compare sinonasal microbiota profiles of patients with malignant tumors (MT), benign tumors (BT), and controls, offering insights into tumor‐
Evan A. Patel +13 more
wiley +1 more source
Ulcerative Manifestations of Hodgkin’s Lymphoma: A Rare Presentation and Its Diagnostic Challenges
Indian Journal of Dermatopathology and Diagnostic DermatologyUlceration as cutaneous presentation of Hodgkin lymphoma (HL) is rare and needs to be differentiated from other dermatological or systemic conditions that present with chronic non-healing ulcers. Although the overall prognosis of Hodgkin lymphoma (HL) is
Shreya Singh +2 more
doaj +1 more source
Annals of Neurology, EarlyView.Cladribine tablets are approved for relapsing multiple sclerosis, mediating their clinical effect by moderately depleting lymphocytes. In a prospective, monocentric study including 22 patients completing 2 annual cycles of cladribine, B‐ and T‐cell receptor repertoires and relapse activity were assessed at baseline and after 24 months. T‐cell clonality
Tilman Schneider‐Hohendorf +8 more
wiley +1 more source
Arthritis &Rheumatology, EarlyView.Objective Antiphospholipid syndrome (APS) is a thromboinflammatory disorder characterized by clinical and mechanistic heterogeneity that complicates early diagnosis and hinders targeted treatment. We aimed to identify distinct molecular endotypes among antiphospholipid antibody (aPL)–positive patients using whole‐blood transcriptomics.
Amala Ambati +13 more
wiley +1 more source
Polish Journal of Microbiology, 2022 The infectious agents may be the etiological factor of up to 15–20% of cancers. In stomach cancer, attention is paid to Helicobacter pylori and Epstein-Barr virus, both of which cause gastritis and can lead to tumor development.
Dzikowiec Magdalena +8 more
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.Spinal muscular atrophy (SMA) is a severe neuromuscular disease with emerging therapeutic complexity. This review aims to systematically map the global pipeline of investigational treatments for SMA. Using ClinicalTrials.gov and complementary international registries, we identified 21 planned or ongoing interventional trials from 2020 to 2025 targeting
Andrej Belančić +7 more
wiley +1 more source